Results 91 to 100 of about 630,325 (166)

Characterization of FcRn_ECD.

, 2013
(A) Representative spectrum of FcRnECD determined by circular dichroism spectroscopy. (B) The pH-dependent interaction between FcRnECD and IgG was investigated by ELISA. Immobilized FcRnECD was probed with human IgG at different pH values.
John Löfblom (110216), Torbjörn Gräslund (486273), Malin Lindborg (486272), Johan Seijsing (486271), Mathias Uhlén (2427553)   +4 more
core   +1 more source

Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China

Neurology and Therapy
Introduction Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder needing long-term immunosuppressive therapy. Eculizumab is a promising treatment, but real-world evidence on its efficacy and safety is limited. Methods This retrospective
Yue Li, Huan Yang, Song Tan, Lijun Luo, Xuebing Cao, JinQuan Hu, Bitao Bu, Ting Chang, Zhijun Li   +8 more
doaj   +1 more source

Interaction of IgG1 glycovariants with FcRn.

, 2015
Comparison of different SPR experimental set-ups: FcRn receptor was captured by Anti-6xHis antibody, followed by the application of IgG glycovariants (black); FcRn was directly immobilized onto the chip surface, subsequently IgG glycovariants were loaded
Johannes Buchner (277160), Tetyana Dashivets (782463), Alexander Knaupp (836559), Tilman Schlothauer (335280), Marco Thomann (782462), Petra Rueger (836558)   +5 more
core   +1 more source

Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice

Frontiers in Immunology
Background and ObjectivesMyasthenia gravis (MG) is a T cell-dependent, B cell-mediated autoimmune disease targeting the acetylcholine receptor (AChR) and other proteins of the neuromuscular junction postsynaptic membrane.
Elena Rinaldi, Elisa Puleo, Alessandra Consonni, Martina Miglietti, Renato Mantegazza, NingXin Wang, Stanford L. Peng, Katherine E. Lewis, Stacey R. Dillon, Fulvio Baggi   +9 more
doaj   +1 more source

Nipocalimab Phase 3 Dose Selection for Severe Hemolytic Disease of the Fetus and Newborn

The Journal of Clinical Pharmacology, Volume 66, Issue 9, September 2026.
Abstract Nipocalimab, a neonatal Fc receptor (FcRn) blocker, is under evaluation for severe hemolytic disease of the fetus and newborn (HDFN). In the Phase 2 UNITY trial, weekly intravenous antenatal treatment with nipocalimab at dose regimens of 30 and 45 mg/kg prevented fetal anemia requiring intrauterine transfusion (IUT) in 54% of high‐risk ...
Jie Zhou, Yuan Xiong, Edwin Lam, Leona E. Ling, Shumyla Saeed‐Khawaja, Yosuke Komatsu, An Vermeulen, Mahesh N. Samtani, Jocelyn H. Leu   +8 more
wiley   +1 more source

Advances in FGF/FGFR Signaling: Implications for Disease and Therapy

MedComm, Volume 7, Issue 9, September 2026.
The FGF/FGFR signaling is indispensable for the maintenance of physiological homeostasis and governs multiple biological processes, including embryonic development, bone metabolism, angiogenesis, and neurogenesis, whereas aberrant hyperactivation of this pathway drives the progression of malignancies and autoimmune disorders, including inflammatory ...
Miaoyu Song, Xi Liu, Yang Xiao, Yongsheng Li, Huakan Zhao   +4 more
wiley   +1 more source

Protein Posttranslational Modifications in Immunity: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 9, September 2026.
Protein posttranslational modifications, including phosphorylation, ubiquitination, SUMOylation, acetylation, methylation, glycosylation, and other new types, dynamically regulate antigen presentation and recognition, immune signal transduction, antibody production and class switching, immune contraction, immune memory establishment, as well as immune ...
Yuxing Yao, Jinxiu Qian, Qiqiong Liu, Wanting Ye, Ying Xing, Xiuyun Bai, Rongjun Deng, Jue Yang, Cheng Lu, Cheng Xiao, Yuanyan Liu   +10 more
wiley   +1 more source

Optimization of the Cell‐Based Assay Methodology to Study Degradation of Acetylcholine Receptors (Antigenic Modulation) by Antibodies From Myasthenia Gravis Patients

Muscle &Nerve, Volume 74, Issue S1, Page S150-S158, September 2026.
ABSTRACT Introduction/Aims Degradation of cell‐surface acetylcholine receptors (AChRs) by antigenic modulation is a key pathogenic mechanism of myasthenia gravis (MG) autoantibodies, yet standard assays primarily detect antibody binding rather than functional effects.
Peng Du, Marina Mané‐Damas, Fien M. Verhamme, Mahan Moshir, Peter Ulrichts, Barbie Machiels, Mario Losen, Pilar Martinez‐Martinez   +7 more
wiley   +1 more source

Abundant intracellular IgG in enterocytes and endoderm lacking FcRn.

, 2013
FcRn, a non-classical MHCI molecule, transports IgG from mother to young and regulates the rate of IgG degradation throughout life. Brambell proposed a mechanism that unified these two functions, saying that IgG was pinocytosed nonspecifically by the ...
Latha P. Ganesan, Latha P Ganesan, Clark L Anderson, Clark L, Jonghan Kim, Gary S Phillips, John M Robinson, Gary S. Phillips, John M. Robinson, Sudhasri Mohanty   +9 more
core   +1 more source

Emergency use of eculizumab in impending and manifest myasthenic crisis: a retrospective case series

Therapeutic Advances in Neurological Disorders
Impending and manifest myasthenic crisis (MC) represent life-threatening neurological emergencies that require immediate intervention. Although eculizumab, a terminal complement C5 inhibitor, has established efficacy in generalized myasthenia gravis ...
Ying Huang, Yihan Xiong, Hui Zhan, Futian Wu, Yichun Jiang, Yaqing Zhang, Jiaxun Chen, Silin Zeng, Ting Zhang, Xiaofeng Xiong, Zhuomin Chen, Fang Yang, Gang Li, Qianhui Xu   +13 more
doaj   +1 more source